• News
  • Europe

Boltz Raises US$110 Million Series A

London-based Boltz secured funding led by Bessemer to expand AI-driven drug discovery tools.

11/19/2026
•Ali Abounasr El Alaoui
Back to News

Boltz raised US$110 million in Series A funding led by Bessemer Venture Partners. The London-based startup builds AI models that speed up drug discovery. It works with pharmaceutical partners including Pfizer, GSK, Takeda, and Bristol Myers Squibb.


Investors in the round

Existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures participated. New investors include Greycroft, F-Prime Capital, Hummingbird, and Benchling. The Series A follows a US$28 million Seed round announced at the start of the year.

Company background

Boltz was founded in 2025 and spun out of MIT. It now employs 40 AI researchers in London's King's Cross district. The startup has signed partnerships with six of the world's 20 largest pharma companies.

Platform and models

Boltz builds software that helps scientists predict how drug candidates bind to proteins. It also estimates binding strength and proposes new molecules designed to bind to a target. Boltz launched Boltz Lab in January, and the company says molecular token usage among paying customers has grown 50-fold since June.


The company plans to use the funding for compute, data, and team expansion. Boltz said its upcoming models already show substantial improvements in generated molecule quality. Its long-term goal is to let a scientist move from a therapeutic hypothesis to a human-ready molecule on a computer.